PDL BioPharma EPS - Earnings per Share 2010-2020 | PDLI
PDL BioPharma eps - earnings per share from 2010 to 2020. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| PDL BioPharma Annual EPS |
| 2020 |
$0.00 |
| 2019 |
$-0.59 |
| 2018 |
$-0.47 |
| 2017 |
$0.71 |
| 2016 |
$0.39 |
| 2015 |
$2.03 |
| 2014 |
$1.86 |
| 2013 |
$1.66 |
| 2012 |
$1.45 |
| 2011 |
$1.15 |
| 2010 |
$0.54 |
| 2009 |
$1.07 |
| PDL BioPharma Quarterly EPS |
| 2020-12-31 |
$0.00 |
| 2020-06-30 |
$-0.43 |
| 2020-03-31 |
$-0.26 |
| 2019-12-31 |
$-0.44 |
| 2019-09-30 |
$-0.16 |
| 2019-06-30 |
$-0.04 |
| 2019-03-31 |
$0.05 |
| 2018-12-31 |
$0.10 |
| 2018-09-30 |
$0.18 |
| 2018-06-30 |
$-0.76 |
| 2018-03-31 |
$0.01 |
| 2017-12-31 |
$0.14 |
| 2017-09-30 |
$0.14 |
| 2017-06-30 |
$0.39 |
| 2017-03-31 |
$0.04 |
| 2016-12-31 |
$-0.06 |
| 2016-09-30 |
$0.08 |
| 2016-06-30 |
$0.03 |
| 2016-03-31 |
$0.34 |
| 2015-12-31 |
$0.64 |
| 2015-09-30 |
$0.42 |
| 2015-06-30 |
$0.47 |
| 2015-03-31 |
$0.50 |
| 2014-12-31 |
$0.29 |
| 2014-09-30 |
$0.61 |
| 2014-06-30 |
$0.52 |
| 2014-03-31 |
$0.44 |
| 2013-12-31 |
$0.32 |
| 2013-09-30 |
$0.36 |
| 2013-06-30 |
$0.62 |
| 2013-03-31 |
$0.36 |
| 2012-12-31 |
$0.32 |
| 2012-09-30 |
$0.32 |
| 2012-06-30 |
$0.52 |
| 2012-03-31 |
$0.29 |
| 2011-12-31 |
$0.24 |
| 2011-09-30 |
$0.28 |
| 2011-06-30 |
$0.38 |
| 2011-03-31 |
$0.25 |
| 2010-12-31 |
$-0.15 |
| 2010-09-30 |
$0.24 |
| 2010-06-30 |
$0.30 |
| 2010-03-31 |
$0.15 |
| 2009-12-31 |
$0.08 |
| 2009-09-30 |
$0.29 |
| 2009-06-30 |
$0.47 |
| 2009-03-31 |
$0.23 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.000B |
$0.055B |
|
Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.
|
